Tizanidine Hydrochloride Capsule
Product Images NDC 70710-1113

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 70710-1113). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals (usa) Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (A619e873 810c 450b Bd4e De0541ed3e63 01)

Chemical structure of tizanidine hydrochloride showing its molecular arrangement including chlorine, nitrogen, sulfur atoms, and the hydrochloride component.*

FDA Label Image

Figure (A619e873 810c 450b Bd4e De0541ed3e63 02)

A pharmacokinetic concentration-time graph showing plasma tizanidine concentration (ng/mL) over 24 hours after dosing. The graph compares 4 mg tizanidine tablets and capsules under conditions with and without food, plotting concentration against hours from dosing with distinct markers for each condition.*

FDA Label Image

Figure (A619e873 810c 450b Bd4e De0541ed3e63 03)

A line graph showing the improvement in Ashworth Score over 6 hours post-dose for 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis represents improvement in Ashworth Score, and the x-axis shows hours post-dose. Data points for each treatment include error bars indicating variability.*

FDA Label Image

Figure (A619e873 810c 450b Bd4e De0541ed3e63 04)

This is a chart comparing the improvement in Ashworth Score over time for tizanidine (mean dose 28.8 mg) versus placebo. The x-axis shows three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The y-axis shows improvement scores ranging from -6 to 2, with tizanidine showing greater improvement (lower scores) compared to placebo at all time points. Error bars indicate variability.*

FDA Label Image

Label (A619e873 810c 450b Bd4e De0541ed3e63 05)

Tizanidine Capsules 2 mg label showing branding by Zydus Pharmaceuticals (USA) Inc. Includes a warning that capsules are not interchangeable with tizanidine tablets or Zanaflex. Package contains 150 capsules for oral use. Lists storage instructions, dosage note, and child-resistant packaging. The label includes an NDC number 70710-1111-8 and mentions the product is distributed by Zydus Pharmaceuticals USA Inc.*

FDA Label Image

Label (A619e873 810c 450b Bd4e De0541ed3e63 06)

Tizanidine Capsules 4 mg oral dosage form in a package containing 150 capsules. The label states it is distributed by Zydus Pharmaceuticals USA Inc. and manufactured by Zydus Lifesciences Ltd. The label includes storage instructions, a warning that the package is child-resistant, and a caution that these capsules are not interchangeable with Zanaflex tablets. The product NDC is 70710-1112-8.*

FDA Label Image

Label (A619e873 810c 450b Bd4e De0541ed3e63 07)

Label for Tizanidine Capsules 6 mg by Zydus Pharmaceuticals (USA) Inc. It is a prescription oral dosage form with 150 capsules per container. The label includes warnings that the product is not interchangeable with tizanidine tablets or Zanaflex tablets and highlights child-resistant packaging. The label also lists storage instructions and manufacturer details as ZyDus Lifesciences Ltd., India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.